From: TAMing pancreatic cancer: combat with a double edged sword
S. No | Curative Agent | Mode of Action | ClinicalTrial.gov ID | Phase | Expected Outcome (with regard to TAMs) |
---|---|---|---|---|---|
1. | Nab-paclitaxel + Gemcitabine + OMP-59R5 | Anti-Notch2/3 Antibody, macropinocytosis | NCT01647828 | II | ↓ M2 origin and polarization |
2. | Olaparib + Cediranib | PARP and VEGFR inhibitor | NCT02498613 | II | ↓ M2 recruitment |
3. | CRS-207 + GVAX ± Nivolumab | Irradiated GM-CSF, listeria antigen, Anti-PD-1 antibody | NCT02243371 | II | ↑ Macrophage count |
4. | Sorafenib + Gemcitabine + Vorinostat + Radiotherapy | VEGFR, PDGFR inhibitor HDAC inhibitor | NCT02349867 | I | ↓M2 recruitment |
5. | Pexidartinib + Durvalumab | CSF-1R, Kit and Flt3 inhibitor, anti-PD-1 antibody | NCT02777710 | I | ↓ M2 polarization |
6. | Pembrolizumab + AMG820 | Anti-PD-1 antibody, anti-CSF1R antibody | NCT02713529 | II | ↓ M2 polarization |
7. | Gemcitabine/Nabpaclitaxel + MM141 | Bispecific Her3 and IGF antibody, macropinocytosis | NCT02399137 | II | ↓ M2 polarization |
8. | Galunisertib + Durvalumab | TGF-β receptor inhibitor, anti-PD-L1 antibody | NCT02734160 | I | ↓ M2 differentiation |
9. | Buparlisib + mFOLFOX6 | PI3K inhibitor | NCT01571024 | I | ↓ M2 polarization |
10. | GVAX + Cyclophosphamide + CRS-207 | Listeria antigen, irradiated GM-CSF | NCT01417000 | II | ↑ Macrophage count |
11. | Gemcitabine/Capecitabine + LY3023414 + Abemaciclib | PI3K/DNA-PK/mTOR inhibitor CDK inhibitor | NCT02981342 | II | ↓ M2 polarization |
12. | Nivolumab + Cabiralizumab | Anti-PD-1 antibody, anti-CSF1R antibody | NCT03599362 | II | ↓ M2 polarization and recruitment |
13. | Nivolumab + cabiralizumab + gemcitabine | Anti-PD-1 antibody, anti-CSF1R antibody | NCT03697564 | IV | ↓ M2 polarization and recruitment |
14. | Cyclophosphamide + GVAX + pembrolizumab + IMC-CS4 | Listeria antigen,Anti-PD-1 antibody | NCT03153410 | I | ↑ Macrophage count and ↓ M2 polarization |
15. | 5-fluorouracil + bevacizumab + leucovorin + oxaliplatin | Anti-VEGF antibody | NCT03127124 | Ib | ↓ M2 recruitment and differentiation |
16. | Capecitabine + temozolomide +/- Bevacizumab | Anti-VEGF antibody | NCT03351296 | II | ↓ M2 recruitment and differentiation |
17. | Palbociclib + Gedatolisib | PI3K/mTOR inhibitor | NCT03065062 | I | ↓ M2 polarization |
18. | Cabiralizumab + nivolumab + gemcitabine + Nabpaclitaxel | Anti-PD-1 antibody, macropinocytosis, anti-CSF1R antibody | NCT03336216 | II | ↓ M2 polarization and recruitment |